Monday, 10 Dec 2018

You are here

Probenecid Benefits Heart Failure

In animal studies, probenecid was shown to have positive inotropic effects on the cardiomyocyte mediated by transient receptor potential vanilloid 2 activation. This concept was further studied in 20 patients with heart failure with reduced ejection fraction where probenecid was shown to improve cardiac function after just one week of probenecid treatment.

Probenecid is thought to exert its effects via calcium channel activation by transient receptor potential vanilloid 2.

Patients were treated in a randomized, double‐blind, crossover design. Clinical performance data were collected and parallel laboratory studies assessed murine cardiomyocytes exposed to probenecid or control treatments.

Probenecid therapy significantly increased fractional shortening by versus placebo (P=0.007) and improved diastolic function compared with placebo.

In vitro probenecid increased myofilament force generation (P<0.05) and calcium sensitivity (P<0.01) compared with control.

These findings suggest that myocardial benefits to probenecid treatment may be related to direct effects on calcium channel signaling rather than the indirect effects of serum urate on renal and vascular function. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Hepatic Safety of Urate Lowering Therapies in Gout

Lee and a group of Korean investigators have analyzed the comparative safety of allopurinol and febuxostat in a small cohort of gout patients with fatty liver disease (FLD) and found febuxostat had a lower risk for hepatotoxicity (defined as AST or ALT at least 3× the upper limit of normal) compared to allopurinol.

Treat-to-Target Strategy Cuts Mortality in Gout Patients

More intense treatment of gout with a treat-to-target strategy can reduce patients' risk for death, a Spanish researcher told a press conference Monday at the American College of Rheumatology annual meeting here.

TRIPLE Trial Results

Pegloticase has become an excellent option for management of patients with chronic refractory gout, although treatment may be limited by the development of anti-drug antibodies that lead to loss of serum urate (sUA) lowering effect.

Gout and the Social Determinants of Health

During a fascinating gout session on October 21, Hyon Choi presented an important paper (abstract 874) which used data from the Health Professionals Follow-up Study to try to understand the rapid increase in the incidence of gout in recent decades.

Nurse Led Gout Management Highly Effective

UK researchers have shown that nurse-led gout management, using a treat-to-target urate-lowering strategy, is efficacious and cost-effective compared with usual physicain care. The results are published in the recent Lancet edition.

Worldwide, gout management is suboptimal. In the UK only 40% of gout patients receive urate-lowering therapy, and fewer ever achieve a target serum urate (< 6mg/d) concentration.